278 related articles for article (PubMed ID: 15919069)
1. Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes.
Meadows LS; Isom LL
Cardiovasc Res; 2005 Aug; 67(3):448-58. PubMed ID: 15919069
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of human arrhythmia syndromes: abnormal cardiac macromolecular interactions.
Mohler PJ; Wehrens XH
Physiology (Bethesda); 2007 Oct; 22():342-50. PubMed ID: 17928548
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and cardiac ion channels.
Roepke TK; Abbott GW
Vascul Pharmacol; 2006 Feb; 44(2):90-106. PubMed ID: 16344000
[TBL] [Abstract][Full Text] [Related]
4. The cardiac sodium channel: gating function and molecular pharmacology.
Balser JR
J Mol Cell Cardiol; 2001 Apr; 33(4):599-613. PubMed ID: 11273715
[TBL] [Abstract][Full Text] [Related]
5. Ryanodine receptors as pharmacological targets for heart disease.
Santonastasi M; Wehrens XH
Acta Pharmacol Sin; 2007 Jul; 28(7):937-44. PubMed ID: 17588328
[TBL] [Abstract][Full Text] [Related]
6. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias.
Dai DZ; Yu F
Acta Pharmacol Sin; 2005 Aug; 26(8):918-25. PubMed ID: 16038623
[TBL] [Abstract][Full Text] [Related]
7. Macromolecular complexes regulating cardiac ryanodine receptor function.
Bers DM
J Mol Cell Cardiol; 2004 Aug; 37(2):417-29. PubMed ID: 15276012
[TBL] [Abstract][Full Text] [Related]
8. Is the ryanodine receptor a target for antiarrhythmic therapy?
Pott C; Goldhaber JI
Circ Res; 2006 May; 98(10):1232-3. PubMed ID: 16728666
[No Abstract] [Full Text] [Related]
9. Cardiac ankyrins: Essential components for development and maintenance of excitable membrane domains in heart.
Cunha SR; Mohler PJ
Cardiovasc Res; 2006 Jul; 71(1):22-9. PubMed ID: 16650839
[TBL] [Abstract][Full Text] [Related]
10. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
11. Arrhythmias of the heart: beyond ion channels.
Marks AR
Nat Med; 2003 Mar; 9(3):263-4. PubMed ID: 12612571
[No Abstract] [Full Text] [Related]
12. Sodium channel (dys)function and cardiac arrhythmias.
Remme CA; Bezzina CR
Cardiovasc Ther; 2010 Oct; 28(5):287-94. PubMed ID: 20645984
[TBL] [Abstract][Full Text] [Related]
13. Two patterns of ion channelopathy in the myocardium: perspectives for development of anti-arrhythmic agents.
Dai DZ
Curr Opin Investig Drugs; 2005 Mar; 6(3):289-97. PubMed ID: 15816506
[TBL] [Abstract][Full Text] [Related]
14. Ryanodine receptor-targeted anti-arrhythmic therapy.
Wehrens XH; Lehnart SE; Marks AR
Ann N Y Acad Sci; 2005 Jun; 1047():366-75. PubMed ID: 16093511
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations and arrhythmia: simulation from DNA to electrocardiogram.
Zhu ZI; Clancy CE
J Electrocardiol; 2007; 40(6 Suppl):S47-50. PubMed ID: 17993328
[TBL] [Abstract][Full Text] [Related]
16. Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction.
Wood DM; Dargan PI; Hoffman RS
Clin Toxicol (Phila); 2009 Jan; 47(1):14-23. PubMed ID: 18815938
[TBL] [Abstract][Full Text] [Related]
17. Ankyrins and human disease: what the electrophysiologist should know.
Mohler PJ
J Cardiovasc Electrophysiol; 2006 Oct; 17(10):1153-9. PubMed ID: 16800854
[TBL] [Abstract][Full Text] [Related]
18. Is it time to include ion channel diseases among cardiomyopathies?
Corrado D; Basso C; Thiene G
J Electrocardiol; 2005 Oct; 38(4 Suppl):81-7. PubMed ID: 16226080
[TBL] [Abstract][Full Text] [Related]
19. Future of antiarrhythmic drugs.
Darbar D; Roden DM
Curr Opin Cardiol; 2006 Jul; 21(4):361-7. PubMed ID: 16755206
[TBL] [Abstract][Full Text] [Related]
20. Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview.
Smits JP; Blom MT; Wilde AA; Tan HL
Expert Opin Pharmacother; 2008 Mar; 9(4):537-49. PubMed ID: 18312156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
